Huang Jane's Insider Trades & SAST Disclosures
Huang Jane's most recent trade in Prelude Therapeutics Inc was a trade of 200,000 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 4, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Huang Jane.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Prelude Therapeutics Inc | Jane Huang | President, CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 200,000 | 200,000 | - | - | Employee Stock Option (right to buy) | |
| Prelude Therapeutics Inc | Jane Huang | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2025 | 9,375 | 72,716 | - | - | Common Stock | |
| Prelude Therapeutics Inc | Jane Huang | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2025 | 9,375 | 46,875 | - | - | Restricted Stock Unit | |
| Prelude Therapeutics Inc | Jane Huang | President, CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.39 per share. | 04 Jan 2025 | 3,859 | 68,857 | - | 1.4 | 5,364 | Common Stock |
| Prelude Therapeutics Inc | Jane Huang | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Oct 2024 | 9,375 | 66,690 | - | - | Common Stock | |
| Prelude Therapeutics Inc | Jane Huang | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Oct 2024 | 9,375 | 56,250 | - | - | Restricted Stock Unit | |
| Prelude Therapeutics Inc | Jane Huang | President, CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.00 per share. | 04 Oct 2024 | 3,349 | 63,341 | - | 2 | 6,698 | Common Stock |
| Prelude Therapeutics Inc | Jane Huang | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jul 2024 | 9,375 | 60,662 | - | - | Common Stock | |
| Prelude Therapeutics Inc | Jane Huang | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jul 2024 | 9,375 | 65,625 | - | - | Restricted Stock Unit | |
| Prelude Therapeutics Inc | Jane Huang | President, CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.60 per share. | 04 Jul 2024 | 3,347 | 57,315 | - | 3.6 | 12,049 | Common Stock |
| Protara Therapeutics Inc | Jane Huang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Prelude Therapeutics Inc | Jane Huang | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2024 | 9,375 | 54,634 | - | - | Common Stock | |
| Prelude Therapeutics Inc | Jane Huang | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2024 | 9,375 | 75,000 | - | - | Restricted Stock Unit | |
| Prelude Therapeutics Inc | Jane Huang | President, CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.74 per share. | 04 Apr 2024 | 3,347 | 51,287 | - | 4.7 | 15,865 | Common Stock |
| Prelude Therapeutics Inc | Jane Huang | President, CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 175,000 | 175,000 | - | - | Employee Stock Option (right to buy) | |
| Prelude Therapeutics Inc | Huang Jane | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2024 | 9,375 | 84,375 | - | - | Restricted Stock Unit | |
| Prelude Therapeutics Inc | Huang Jane | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2024 | 9,375 | 49,103 | - | - | Common Stock | |
| Prelude Therapeutics Inc | Jane Huang | President, CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.77 per share. | 04 Jan 2024 | 3,844 | 45,259 | - | 3.8 | 14,492 | Common Stock |
| Prelude Therapeutics Inc | Jane Huang | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jul 2023 | 9,375 | 103,125 | - | - | Restricted Stock Unit | |
| Prelude Therapeutics Inc | Jane Huang | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jul 2023 | 9,375 | 33,595 | - | - | Common Stock | |
| Prelude Therapeutics Inc | Jane Huang | President, CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.65 per share. | 04 Jul 2023 | 3,242 | 30,353 | - | 4.6 | 15,075 | Common Stock |
| Protara Therapeutics Inc | Jane Huang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Prelude Therapeutics Inc | Jane Huang | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2023 | 37,500 | 112,500 | - | - | Restricted Stock Unit | |
| Prelude Therapeutics Inc | Jane Huang | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2023 | 37,500 | 37,500 | - | - | Common Stock | |
| Prelude Therapeutics Inc | Jane Huang | President, CMO | Sale of securities on an exchange or to another person at price $ 6.12 per share. | 04 Apr 2023 | 13,280 | 24,220 | - | 6.1 | 81,274 | Common Stock |
| Prelude Therapeutics Inc | Jane Huang | President, CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 150,000 | 150,000 | - | - | Employee Stock Option (right to buy) | |
| Protara Therapeutics Inc | Jane Huang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Prelude Therapeutics Inc | Jane Huang | President, CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 460,000 | 460,000 | - | - | Employee Stock Option (Right to Buy) | |
| Prelude Therapeutics Inc | Jane Huang | President, CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 150,000 | 150,000 | - | - | Restricted Stock Unit | |
| Protara Therapeutics Inc | Jane Huang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Protara Therapeutics Inc | Jane Huang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges